AIN457 in patients with moderate to severe ankylosing spondylitis

• Research type

  Research Study

• Full title

  Randomized, placebo controlled double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis

• IRAS ID

  7226

• Sponsor organisation

  Novartis Pharmaceuticals

• Eudract number

  2008-002631-33

• ISRCTN Number

  N/A

• Research summary

  The study is designed to show the Effectiveness of AIN457, after 6 weeks of use, in patients with moderate to severe ankylosing spondylitis. patients and physicians work together to complete various questionnaires assessing the pain, stiffness and flexibility of the patient.

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  08/H1208/47

• Date of REC Opinion

  14 Jan 2009

• REC opinion

  Further Information Favourable Opinion